TITLE

Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

AUTHOR(S)
Kensaku Kasuga
PUB. DATE
June 2010
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun2010, Vol. 81 Issue 6, p608
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: The clinical diagnosis of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of α-synuclein, β-amyloid42 (Aβ42) and tau in the CSF of patients with DLB, Alzheimer's disease (AD) and other dementias was examined. METHODS: 86 patients were divided into three age and sex matched groups: DLB (n=34), AD (n=31) and other dementias (n=21). Two patients with α-synuclein gene (SNCA) duplication were also examined. Aβ and tau were quantified using an ELISA kit. A modified sandwich ELISA was developed which enables the sensitive quantification of CSF α-synuclein. RESULTS: Total and phosphorylated tau levels as well as Aβ40/42 and tau/Aβ42 ratios were significantly higher in AD patients than in patients with DLB (p<0.01) and other dementias (p<0.01). CSF α-synuclein levels in DLB patients were significantly lower than those in patients with AD (p<0.05) and other dementias (p<0.01). CSF α-synuclein level correlated with the Aβ42 level in DLB patients (p=0.01, r=0.43). Two patients with SNCA duplication exhibited relatively low levels of CSF α-synuclein. CONCLUSIONS: The study suggests that reduced levels of CSF α-synuclein in DLB may reflect the accumulation of α-synuclein with Lewy pathology in the brain and that quantification of CSF α-synuclein helps in the differentiation of DLB from AD and other dementias in combination with Aβ42 and tau analysis.
ACCESSION #
51333521

 

Related Articles

  • Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. Wennström, Malin; Surova, Yulia; Hall, Sara; Nilsson, Christer; Minthon, Lennart; Boström, Fredrik; Hansson, Oskar; Nielsen, Henrietta M. // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Neurosin is a protease that in vitro degrades α-synuclein, the main constituent of Lewy bodies found in brains of patients with synucleinopathy including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Several studies have reported reduced cerebrospinal fluid (CSF) levels of...

  • CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Toledo, Jon; Korff, Ane; Shaw, Leslie; Trojanowski, John; Zhang, Jing // Acta Neuropathologica;Nov2013, Vol. 126 Issue 5, p683 

    Alzheimer's disease (AD) and Lewy body diseases (LBD), e.g., Parkinson's disease (PD) dementia and dementia with Lewy bodies (DLB), are common causes of geriatric cognitive impairments. In addition, AD and LBD are often found in the same patients at autopsy; therefore, biomarkers that can detect...

  • Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Wennström, Malin; Hall, Sara; Nägga, Katarina; Londos, Elisabet; Minthon, Lennart; Hansson, Oskar // Alzheimer's Research & Therapy;10/5/2015, Vol. 7 Issue 1, p1 

    Introduction: Inflammatory processes have previously been shown to influence cognition and progression of dementia. An involvement of interleukin (IL)-6 has in particular been suggested as altered levels of IL-6 in cerebrospinal fluid (CSF) have been found in patients with Alzheimer's disease...

  • Combining Biomarkers Improves Detection of Dementia Subtypes.  // Neurology Reviews;Nov2010, Vol. 18 Issue 11, p1 

    The article reports on research from physician James E. Galvin which shows that the combination of two chronic fatigue syndrome (CSF) amyloid-beta 42 and alpha-synuclein biomarkers may improve detection of dementia subtypes. It discusses the difference between Alzheimer's disease and dementia...

  • Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. Mulugeta, Ezra; Londos, Elisabet; Hansson, Oskar; Ballard, Clive; Skogseth, Ragnhild; Minthon, Lennart; Blennow, Kaj; Zetterberg, Henrik; Aarsland, Dag // International Journal of Alzheimer's Disease;2011, Vol. 2011, p1 

    We measured cerebrospinal fluid (CSF) levels of the soluble isoforms of amyloid precursor protein (APP; sAPPα sAPPβ) and other CSF biomarkers in 107 patients with Alzheimer's disease (AD), dementia with Lewy body dementia (DLB), Parkinson's disease dementia (PDD), and normal controls (NC)...

  • Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck, Tobias; Farahmand, Bahman Y.; Rosén, Christoffer; Mattsson, Niklas; Nägga, Katarina; Kilander, Lena; Religa, Dorota; Wimo, Anders; Winblad, Bengt; Schott, Jonathan M.; Blennow, Kaj; Eriksdotter, Maria; Zetterberg, Henrik // Brain: A Journal of Neurology;Sep2015, Vol. 138 Issue 9, p2716 

    Progressive cognitive decline in combination with a cerebrospinal fluid biomarker pattern of low levels of amyloid-β1-42 and high levels of total tau and phosphorylated tau is typical of Alzheimer's disease. However, several neurodegenerative disorders may overlap with Alzheimer's disease...

  • Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck, Tobias; Farahmand, Bahman Y; Rosén, Christoffer; Mattsson, Niklas; Nägga, Katarina; Kilander, Lena; Religa, Dorota; Wimo, Anders; Winblad, Bengt; Schott, Jonathan M; Blennow, Kaj; Eriksdotter, Maria; Zetterberg, Henrik // Brain: A Journal of Neurology;Sep2015, Vol. 138 Issue 9, p2716 

    Progressive cognitive decline in combination with a cerebrospinal fluid biomarker pattern of low levels of amyloid-β1-42 and high levels of total tau and phosphorylated tau is typical of Alzheimer's disease. However, several neurodegenerative disorders may overlap with Alzheimer's disease...

  • CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies. Bibl, M.; Mollenhauer, B.; Esselmann, H.; Lewczuk, P.; Trenkwalder, C.; Brechlin, P.; Rüther, E.; Kornhuber, J.; Otto, M.; Wiltfang, J. // Journal of Neural Transmission;Nov2006, Vol. 113 Issue 11, p1771 

    Differential diagnosis of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) is often crucial. CSF Tau protein and Amyloid-beta (Aβ) peptides have shown diagnostic value for the diagnosis of AD, but discrimination from DLB was poor. Herein, we investigate CSF of 18 patients...

  • Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia. Maetzler, Walter; Youyong Tian; Baur, Stephanie Maria; Gauger, Tina; Odoj, Bartholomäus; Schmid, Benjamin; Schulte, Claudia; Deuschle, Christian; Heck, Susanna; Apel, Anja; Melms, Arthur; Gasser, Thomas; Berg, Daniela // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Parkinson's disease (PD) without (non-demented, PDND) and with dementia (PDD), and dementia with Lewy bodies (DLB) are subsumed under the umbrella term Lewy body disorders (LBD). The main component of the underlying pathologic substrate, i.e. Lewy bodies and Lewy neurites, is misfolded...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics